LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced that its hospital-based products business, Abraxis Pharmaceutical Products (APP), has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Caffeine Citrate injection, USP, 20 mg/mL, the generic equivalent of Cafcit® Injection manufactured by Mead Johnson and Company. According to IMS data, annual sales in 2006 of this product across all distributors and dosage forms were approximately $16 million. APP will package this product in 60 mg/3mL single-use vials and expects to commence marketing of this product immediately.
